摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-propyl-piperidin-1-yl)-methanone

中文名称
——
中文别名
——
英文名称
[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-propyl-piperidin-1-yl)-methanone
英文别名
Rac-(5-chloro-6-(6-methylpyridin-3-ylamino)pyridin-3-yl)(2-propylpiperidin-1-yl)methanone;[5-chloro-6-[(6-methylpyridin-3-yl)amino]pyridin-3-yl]-(2-propylpiperidin-1-yl)methanone
[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-propyl-piperidin-1-yl)-methanone化学式
CAS
——
化学式
C20H25ClN4O
mdl
——
分子量
372.898
InChiKey
JFVQMYLXIIQSQB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    26
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    58.1
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    5-chloro-6-(6-methylpyridin-3-ylamino)nicotinic acid2-丙基哌啶N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下, 以 乙二醇二甲醚 为溶剂, 反应 6.0h, 生成 [5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-propyl-piperidin-1-yl)-methanone
    参考文献:
    名称:
    Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity
    摘要:
    High throughput screening led to the identification of nicotinamide derivative 2 as a structurally novel mGluR5 antagonist. Optimization of the modular scaffold led to the discovery of 16m, a compound with high affinity for mGluR5 and excellent selectivity over other glutamate receptors. Compound 16m exhibits a favorable PK profile in rats, robust anxiolytic-like effects in three different animal models of fear and anxiety, as well as a good PK/PD correlation. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.11.001
点击查看最新优质反应信息

文献信息

  • Organic Compounds
    申请人:Glatthar Ralf
    公开号:US20090005363A1
    公开(公告)日:2009-01-01
    The present invention relates to novel nicotinic acid derivatives, of formula (I) wherein the substituents are defined in the specification, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
    本发明涉及新的烟酸衍生物,其化学式为(I),其中取代基在规范中定义,其制备方法,其作为药物的用途以及含有它们的药物组合物。
  • USES OF METABOTROPIC GLUTAMATE RECEPTORS
    申请人:Ralf Glatthar
    公开号:US20100041641A1
    公开(公告)日:2010-02-18
    The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.
    本发明涉及使用mGluR调节剂,例如mGluR5调节剂,用于治疗、预防或延缓认知功能障碍的进展。
  • USE OF METABOTROPIC GLUTAMATE RECEPTORS
    申请人:GLATTHAR Ralf
    公开号:US20120309742A1
    公开(公告)日:2012-12-06
    The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.
    本发明涉及使用mGluR调节剂,例如mGluR5调节剂,用于治疗、预防或延缓认知功能障碍的进展。
  • New Uses of metabotropic glutamate receptors
    申请人:Novartis AG
    公开号:EP2272509A1
    公开(公告)日:2011-01-12
    The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.
    本发明涉及使用 mGluR 调节剂(如 mGluR5 调节剂)治疗、预防或延缓认知功能障碍的进展。
  • Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity
    作者:Carsten Spanka、Ralf Glatthar、Sandrine Desrayaud、Markus Fendt、David Orain、Thomas Troxler、Ivo Vranesic
    DOI:10.1016/j.bmcl.2009.11.001
    日期:2010.1
    High throughput screening led to the identification of nicotinamide derivative 2 as a structurally novel mGluR5 antagonist. Optimization of the modular scaffold led to the discovery of 16m, a compound with high affinity for mGluR5 and excellent selectivity over other glutamate receptors. Compound 16m exhibits a favorable PK profile in rats, robust anxiolytic-like effects in three different animal models of fear and anxiety, as well as a good PK/PD correlation. (C) 2009 Elsevier Ltd. All rights reserved.
查看更多